Search
for
Sort by
Research 751–780 of 1000+
- Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
- Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
- Topical Janus kinase inhibitors: A review of applications in dermatology
- The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus
- 72751 Janus Kinase Inhibitors for Alopecia Universalis: A Systematic Review
- Homogenization theory captures macroscopic flow discontinuities across Janus membranes
- P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
- Dupilumab and alopecia: A Janus effect
- Body temperature-responsive Janus patches accelerate diabetic wound regeneration via coupling mechanical transduction and biochemical pathways
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Confusion Over Use: Contextualism in Trademark Law (with M. Janis)
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Alopecia areata
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Leptin and the skin: a new frontier
- Topical Ruxolitinib for the Treatment of Alopecia Universalis
- Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies
- Tofacitinib for the treatment of lichen planopilaris: A case series
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- JAK Inhibitors for Treatment of Alopecia Areata
- Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention
- JAK inhibitors and alopecia areata
- Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
- Treatment of pediatric alopecia areata: A systematic review
- Pathomechanisms of immune-mediated alopecia
- Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis